In vitro activities of linezolid, meropenem, and quinupristin-dalfopristin against group C and G streptococci, including vancomycin-tolerant isolates.
The in vitro activities of meropenem, linezolid, quinupristin-dalfopristin, vancomycin, and penicillin against 130 clinical isolates of group C and G streptococci, including vancomycin-tolerant isolates, were evaluated. Meropenem, linezolid, quinupristin-dalfopristin, vancomycin, and penicillin MICs at which 90% of the isolates were inhibited were 0.06, 2.0, 0.25, 0.5, and < or = 0.016 microg/ml, respectively. Meropenem, linezolid, quinupristin-dalfopristin, and penicillin were active against group C and G streptococci, including vancomycin-resistant strains.
Zaoutis
T
T
Division of Pediatric Infectious Diseases, Alfred I. duPont Hospital for Children, Wilmington, Delaware, USA.
Moore
L S
LS
Furness
K
K
Klein
J D
JD
D000081:Acetamides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006801:Humans; D000069349:Linezolid; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000494:pharmacology; D010403:Penicillin Resistance; D013291:Streptococcus / Q000187:drug effects*; D013845:Thienamycins / Q000494:pharmacology; D020713:Vancomycin Resistance; D014769:Virginiamycin / Q000494:pharmacology
D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D013845:Thienamycins; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D000077731:Meropenem; D000069349:Linezolid